Adalimumab Plus Methotrexate Promising for Psoriasis
The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.
The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.
Dermatologists are well positioned to recognize the signs of systemic disease, explains Torunn Sivesind, MD, a dermatology fellow at the University of Colorado Anschutz Medical Campus in Colorado.